Results 61 to 70 of about 274 (96)

Abstract 443: Predictors of mortality in hospitalized African American COVID19 cancer patients

Cancer Research, 2022
Background: Coronavirus disease 2019 (COVID-19) and associated outcomes manifest differently depending on patients’ background and pre-existing conditions. It remains unclear how African Americans with and without cancer have been affected.
S. Challa, L. Chirumamilla, Nader A. Shayegh, Josie Z. Fazzino, A. Laiyemo, philip Oppong-Twene, Z. Sherif, Oluwabusola Olamide Lawal, D. Larbi, G. Oskrochi, H. Brim, Hassan Ashktorab   +11 more
semanticscholar   +1 more source

Abstract 4118: Brain metastases (BM) and next-generation sequencing (NGS) timing: Real-world (RW) outcomes for patients (pts) with advanced non-small cell lung cancer (aNSCLC) and MET exon 14 skipping mutations (METex14)

Cancer Research, 2022
Background: Treatment (Tx) options for METex14 NSCLC have been limited to chemotherapy (Ctx), immunotherapy (IO), and multikinase inhibitors (MKi) until FDA approvals of selective MET inhibitors (METi) from 2020. BM are a further challenge to treat. We
X. Le, S. Robb, N. Caro, S. Doria, W. Rhodes, Wen-Hsing Wu, Julia Kim, V. Pretre, Fen Ye   +8 more
semanticscholar   +1 more source

Virtual Communication and its Negative Impact on the Generation of Creative Ideas

International Journal of Clinical Studies and Medical Case Reports, 2022
During the Covid-19 pandemic, the global scenario changed and the people had to adapt to social isolation, which led to an increase in the utilization of remote technologies in multiple areas.
J. C. Claudino dos Santos
semanticscholar   +1 more source

Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

Cancer Research, 2022
Background: KRAS G12C oncogenic mutations occur in ~13% of non-small cell lung cancers (NSCLCs) and up to 4% of other solid tumors. JDQ443 is a selective, covalent, orally bioavailable, investigational KRASG12C inhibitor that irreversibly traps ...
D. Tan, Toshio Shimizu, B. Solomon, R. Heist, M. Schuler, M. D. M. Luken, A. Gazzah, M. Wermke, C. Dooms, H. Loong, N. Steeghs, E. Felip, C. Steuer, E. Van Cutsem, R. Soo, Ashley C. Jaeger, Jaeyeon Kim, Kun Xu, Xueying Chen, Xiaoming Cui, H. Burks, A. Farago, P. Cassier   +22 more
semanticscholar   +1 more source

Abstract CT015: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer

Cancer Research, 2022
Background: The ecto-ATPase CD39 is the rate-limiting enzyme in the adenosine pathway that plays an important immune regulatory role. Preclinically, inhibition of CD39 by TTX-030, a first-in-class fully human anti-CD39 antibody, reversed ...
Z. Wainberg, Yoon-Koo Kang, Keun-Wook Lee, Seung-Tae Kim, J. Chao, D. Catenacci, S. Oh, Heloisa P Soares, J. Selfridge, Y. Cha, R. Skeel, Hyung-Don Kim, Anh Tran, Achim K. Moesta, Tracy dela Cruz, A. Singhal, Tom Jahn, F. Dayyani   +17 more
semanticscholar   +1 more source

Abstract CT183: First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors

Cancer Research, 2022
Background: IL-12 is a key mediator of antitumor immune response. In preclinical models, IT IL-12 mRNA led to IFNγ release and CD8+ T cell-dependent tumor regression and potentiated PD-L1 blockade.
B. Carneiro, D. Zamarin, T. Marron, I. Mehmi, S. P. Patel, V. Subbiah, A. El-Khoueiry, D. Grand, K. García-Reyes, S. Goel, Phillip Martin, Jixin Wang, Yuling Wu, Steve Eck, Benjamin Ridgway, N. Elgeioushi, J. Eyles, N. Durham, A. Azaro, Omidvarborna Hamid   +19 more
semanticscholar   +1 more source

Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation

Cancer Research, 2022
Background: KRASG12C mutation is an oncogenic driver that occurs in approximately 15% of non-small cell lung cancer (NSCLC), 3% of colorectal cancer (CRC), and ~1% of several other solid tumors.
Timothy Price, J. Grewal, A. Abed, Melissa M Moore, Yu-Min Yeh, S. Gadgeel, G. Richardson, C. Underhill, V. Ganju, Keun-Wook Lee, S. Huh, Sang-We Kim, Chih‐Hsin Yang, Yuh-Min Chen, Ziyong Xiang, Zhe Shi, Yaolin Wang, Ling Zhang, Michael Millward   +18 more
semanticscholar   +1 more source

Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma

Cancer Research, 2022
Background: MAPK pathway dysregulation is a characteristic molecular abnormality of melanoma. NRAS mutations in melanoma lead to constitutive MAPK activation and subsequent MEK and ERK activation.
F. de Braud, C. Dooms, R. Heist, C. Lebbé, M. Wermke, D. Planchard, D. Schadendorf, P. Rutkowski, J. Wolf, P. Ascierto, I. Gil-Bazo, S. Kato, Maria Wolodarski, M. McKean, E. M. Couselo, M. Sebastian, A. Santoro, V. Cooke, L. Manganelli, K. Wan, Anil Gaur, T. Samant, Jaeyeon Kim, G. Caponigro, Xuân-Mai Couillebault, M. Moschetta, A. Daud   +26 more
semanticscholar   +1 more source

Abstract 916: Dec2, a circadian rhythm gene is necessary for disseminated tumor cell survival in a novel murine model of pancreatic cancer dormancy

Cancer Research, 2022
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a proclivity for early metastasis. Resection remains the only chance for long term survival though most patients die from metastatic recurrence. While most patients recur within
A. Casabianca, Chris J. Harris, C. Dudgeon, D. Carpizo   +3 more
semanticscholar   +1 more source

Abstract 6305: Downregulation of glutamine transporter stably and significantly attenuates weight loss by a cachexia-inducing pancreatic cancer xenograft

Cancer Research, 2022
Cancer-induced cachexia is commonly observed in pancreatic cancer. The syndrome induces significant weight loss and leads to morbidity, intolerance to chemotherapy, and mortality.
B. Krishnamachary, Ishwarya Sivakumar, Y. Mironchik, R. K. Sharma, S. Bharti, Marie-France Penet, P. Winnard, E. Goggins, Jiefu Jin, A. Maitra, M. Goggins, Z. Bhujwalla   +11 more
semanticscholar   +1 more source